Monoamine oxidase and oxidative stress at dopaminergic synapses

  • G. Cohen
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)


Increased oxidation of dopamine by monoamine oxidase (MAO) in the striatum is associated with an oxidant stress, expressed as a rise in the level of oxidized glutathione. Oxidation of glutathione is suppressed by MAO inhibitors, such as deprenyl and clorgyline. These observations relate to Parkinson’s disease and to the clinical trial of deprenyl as an agent that may retard progression of the disease.


Oxidize Glutathione Glutathione Disulfide GSSG Level Peroxidative Stress Nigrostriatal Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams JD, Lauterberg EH, Mitchell JR (1983) Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther 227:749–754.PubMedGoogle Scholar
  2. Akerboom TPM, Sies H (1981) Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Meth Enzymol 77:373–382.PubMedCrossRefGoogle Scholar
  3. Altar CA, Marien MR, Marshall JF (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J Neurochem 48:390–399.PubMedCrossRefGoogle Scholar
  4. Birkmayer W, Knoll J, Riederer P, Youdim M, Hars V, Marton J (1985) Increased life expectancy resulting from the addition of L-deprenyl to Madopar therapy in Parkinson’s disease. J Neural Transm 64:113–127.PubMedCrossRefGoogle Scholar
  5. Cohen G (1983) The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl] 19:89–103.Google Scholar
  6. Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26:689–690.PubMedCrossRefGoogle Scholar
  7. Hefti F, Melamed E, Wurtman RJ (1980) Partial lesions of the dopaminergic nigrostriatal system: biochemical characterization. Brain Res 195:123–137.PubMedCrossRefGoogle Scholar
  8. Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Parkinson’s disease. Raven Press, New York (Adv Neurol 45:19–34).Google Scholar
  9. Kindt MV, Youngster SK, Sonsalla PK, Duvoisin R, Heikkila RE (1988) Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2′Me-MPTP. Eur J Pharmacol 146:313–318.PubMedCrossRefGoogle Scholar
  10. Parkinson Study Group (1989a) DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 46:1052–1060.CrossRefGoogle Scholar
  11. Parkinson Study Group (1989b) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321:1364–1371.CrossRefGoogle Scholar
  12. Slivka A, Spina MB, Cohen G (1987) Reduced and oxidized glutathione in human and monkey brain. Neurosci Lett 74:112–118.PubMedCrossRefGoogle Scholar
  13. Spina MB, Cohen G (1988) Exposure of striatal synaptosomes to L-dopa elevates levels of oxidized glutathione. J Pharmacol Exp Ther 247:502–507.PubMedGoogle Scholar
  14. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson’s disease. Proc Natl Acad Sci (USA) 86:1398–1400.CrossRefGoogle Scholar
  15. Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502–522.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • G. Cohen
    • 1
  1. 1.Department of Neurology and Neurobiology CenterMount Sinai School of MedicineNew YorkUSA

Personalised recommendations